Anupam Rasayan Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Published 25 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹14.2K Cr

Organic revenue growth expected at around 25% ± a couple of percentage points annually. - Addition of Jayhawk's revenue contributes an incremental 10% to 15% growth, as Jayhawk was not included in previous years. - Overall growth from existing three companies (Anupam, Tanfac, Jayhawk) anticipated to be strong, with Jayhawk contributing approx. Organic revenue growth expected around 25% (+/- a few percentage points) for FY27 from existing companies (Anupam, Tanfac), plus an additional 10-15% growth from Jayhawk's inclusion.

From Anupam Rasayan's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

📊 Revenue & Sales Performance

Rank 2

→Organic revenue growth expected at around 25% ± a couple of percentage points annually.
→Addition of Jayhawk's revenue contributes an incremental 10% to 15% growth, as Jayhawk was not included in previous years.
→Overall growth from existing three companies (Anupam, Tanfac, Jayhawk) anticipated to be strong, with Jayhawk contributing approx. INR140-150 crores this quarter.
→Growth excluding Jayhawk was single-digit, reflecting a seasonal tepid Q1.
→Post-consummation of Bliss GVS Pharma acquisition, further growth expected by improving asset utilization from current ~30% to 60-70% over 2-3 years.
→Bliss integration will likely stimulate growth via combined sales and marketing efforts.
→Long term opportunities exist with new product pipelines and LOIs such as BASQUEVOLT (~USD300 million over 10 years).
→Stable growth expected across Agri, Pharma, and Performance Materials segments with shifting portfolio mix.

📈 Profitability & Margins

Rank 3

→Organic revenue growth expected around 25% (+/- a few percentage points) for FY27 from existing companies (Anupam, Tanfac), plus an additional 10-15% growth from Jayhawk's inclusion.
→Bliss acquisition anticipated to improve utilization from ~30% to 60-70% over 2-3 years, supporting future revenue and margin expansion.
→EBITDA margins expected to stabilize in the range of 22-24% consolidated and 24-26% standalone over the next 2-3 years.
→PAT growth was 6% YoY in Q1 FY27 despite 35% EBITDA growth, due partly to increased depreciation and interest from the expanded asset base.
→Future profit growth to improve as new product commercialization scales and operational efficiencies increase.
→Capex largely completed; focus on selective investments based on customer visibility and returns, limiting margin pressure.
→Working capital efficiency expected to improve, supporting cash flow and profitability expansion over time.

See what Anupam Rasayan said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→Major capex cycle for existing Anupam platform has been completed, with all major projects commissioned and operational. (Page 6)
→Future capex expected to be limited, primarily for repair, maintenance, repurposing, or new product introductions. (Page 9)
→Guided capex range for FY27 is approximately INR 70-80 crores, focused mainly on standalone business. (Page 9)
→Jayhawk is well capitalized, unlevered, and expected to fund its own capex for growth, repurposing, or replacements without Anupam's funding support, at least in near term. (Page 9)
→Strategic investments include the ongoing Bliss GVS Pharma acquisition (expected to close by H1 September), which will expand pharmaceutical capabilities. (Pages 6-16)
→Letter of Intent with BASQUEVOLT involves potential long-term revenue of ~USD 300 million over 10 years, with commercialization expected from FY27. (Page 5)

💰 Fundraising & Capital Structure

Yes

→For the Bliss acquisition, a debt of around INR 300 crores is planned through a fully owned subsidiary of Anupam to acquire the stake from selling shareholders.
→Bliss itself has healthy cash flow (~INR 200+ crores) and no debt, so they do not foresee a large external capital requirement for any API asset acquisition; internal accruals are expected to be sufficient.
→Any further funding needed by Bliss may come from leveraging their robust balance sheet or internal working capital like receivables.
→Apart from this, Anupam does not currently see a major capex or capital raising requirement; the major capex cycle is complete with only selective incremental spend planned (~INR 70-80 crores).
→Interest costs are expected to remain at current run rates without significant increases.
→Anupam continues to explore acquisition opportunities, but no specific new fundraising for those is indicated at this stage.

See what Anupam Rasayan said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

Yes

→The order book revenue for the last year was roughly around INR 400 crores.
→This revenue is expected to be significantly higher this year, contributing around 25% of total revenue.
→Going forward, the order book is anticipated to contribute around 30% of total revenue.
→Most products in the order book have been or are expected to be commercialized by this year or the next year.
→Overall, there is a strong ramp-up occurring in the order book execution and conversion to revenue.

Key Metrics

2 of 5 growth signals positive in the Q1 FY27 call.

Revenue

Rank 2

Margin

Rank 3

Capex

Fundraise

Yes

Order Book

Yes

How does Anupam Rasayan rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Anupam Rasayan

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

Price

₹1,263

Market Cap

₹14.2K Cr

P/E Ratio

81.0

Anupam Rasayan — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹636 Cr, net profit ₹56 Cr.

Full financials →

What ANURAS's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Sudarshan Chemical Industries Ltd (Q1 FY27)
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
Indo Borax & Chemicals Ltd (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
SRF Ltd (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
Deepak Fertilisers & Petrochemicals Corp Ltd (Q1 FY27)
Long-term demand-supply balance looks stable with 6-7% market growth, supporting sustained revenues despite new capacity additions. Key concall takeaways from…

Compare:vs Solar Industries India Ltd vs PIDILITIND vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Anupam Rasayan Q1 FY27 results?

What is Anupam Rasayan share price analysis?

Anupam Rasayan currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 81.0 with a market cap of ₹14,160 Cr. Investors should review the full earnings analysis for detailed insights.

Is Anupam Rasayan planning capital expenditure?

Major capex cycle for existing Anupam platform has been completed, with all major projects commissioned and operational.

Keep Anupam Rasayan on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.